CN1120173C - Antitumor substance extracted from Grifola - Google Patents
Antitumor substance extracted from Grifola Download PDFInfo
- Publication number
- CN1120173C CN1120173C CN97192894A CN97192894A CN1120173C CN 1120173 C CN1120173 C CN 1120173C CN 97192894 A CN97192894 A CN 97192894A CN 97192894 A CN97192894 A CN 97192894A CN 1120173 C CN1120173 C CN 1120173C
- Authority
- CN
- China
- Prior art keywords
- dextran
- liquid
- water
- extracting solution
- protein complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000222684 Grifola Species 0.000 title claims description 6
- 239000000126 substance Substances 0.000 title abstract description 20
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 240000001080 Grifola frondosa Species 0.000 claims abstract description 11
- 235000007710 Grifola frondosa Nutrition 0.000 claims abstract description 11
- 238000000605 extraction Methods 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 18
- 229920002307 Dextran Polymers 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 241000589516 Pseudomonas Species 0.000 claims description 10
- 238000001556 precipitation Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 abstract description 6
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 230000002434 immunopotentiative effect Effects 0.000 abstract 2
- 238000005194 fractionation Methods 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000002622 anti-tumorigenesis Effects 0.000 description 4
- 238000007667 floating Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 239000006035 Tryptophane Substances 0.000 description 2
- OMOVVBIIQSXZSZ-UHFFFAOYSA-N [6-(4-acetyloxy-5,9a-dimethyl-2,7-dioxo-4,5a,6,9-tetrahydro-3h-pyrano[3,4-b]oxepin-5-yl)-5-formyloxy-3-(furan-3-yl)-3a-methyl-7-methylidene-1a,2,3,4,5,6-hexahydroindeno[1,7a-b]oxiren-4-yl] 2-hydroxy-3-methylpentanoate Chemical compound CC12C(OC(=O)C(O)C(C)CC)C(OC=O)C(C3(C)C(CC(=O)OC4(C)COC(=O)CC43)OC(C)=O)C(=C)C32OC3CC1C=1C=COC=1 OMOVVBIIQSXZSZ-UHFFFAOYSA-N 0.000 description 2
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 235000007714 Laetiporus sulphureus Nutrition 0.000 description 1
- 240000005995 Laetiporus sulphureus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- -1 Xie Ansuan Chemical compound 0.000 description 1
- 231100000987 absorbed dose Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/375—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Basidiomycetes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
An antitumor substance obtained from the mycelia or fruit bodies of hen-of-the-woods (grifola frondosa) by extraction and fractionation and having a potent immunopotentiating activity. The antitumor activity and immunopotentiating power can be enhanced by extracting the mycelia or fruit bodies with hot water and adding alcohol to the extract in a final concentration of 20 to 70 % by volume (low-concentration addition) to remove the suspension or deposits.
Description
Field of the present invention
The present invention relates to have the antitumorigenic substance of high immune-enhancing activity, this material is to extract from mycelium of " Maitake " mushroom (tree flower Pseudomonas) or sporophore and fractional separation obtains.
The technology of the present invention background
Known from the mycelium of setting colored Pseudomonas or sporophore extract by having β-1, the 3-key connects the β-1 of branched glucose, the 6-key connects that the glucose main chain constitutes or by having β-1, the 6-key connects the β-1 of branched glucose, and the polysaccharide that the 3-key connects glucose main chain formation has antitumour activity (referring to the open No.210901/1984 of Japanese Patent LOP).
It also is known comprising the following steps to prepare cancer-resisting substance, and described step is: with hot water to Grifola frondosa, tree flower Pseudomonas resemble ear orchid (Grifola gigantea) (Tonbimai) or Laetiporussulphureus (Masutake) extract; The concentrating under reduced pressure extracting solution precipitates concentrated solution with organic solvent, throw out is dialysed removing low-molecular-weight material, and with lipophilic organic solvent extraction impurity from dialyzate, to remove them.(referring to the open No.16047/1968 of Japanese Patent).
Yet, those methods of describing among open No.210901/1984 of Japanese Patent LOP and the open No.16047/1968 of Japanese Patent, prepare effectively for a large amount of medicament of preparation with from limited resources and not to be well suited for for the heath food, because the purification step of these methods is quite complicated, and contains the material that suppresses immune-enhancing activity in the product of gained.
Of the present invention open
In the case, the inventor to the method for extracting tree flower bacterium and thus the various extracts of method gained carried out deep research.Found that the antitumorigenic substance that obtains to have higher immune-enhancing activity effectively is possible.Be primarily characterized in that, by to the mycelium of setting colored Pseudomonas or sporophore water are carried out heat extract add in the water-soluble extracting liquid that get pure to the volume final concentration be 20-70% (lower concentration interpolation), remove the buoyant material or be attached to material on the wall of container, thereby improve anti-tumor activity and immune-enhancing activity.
That is to say, the present invention relates to have the dextran/protein complex of immune-enhancing activity and comprise the anti-tumor agent comprising salmosin of this mixture that described mixture is got by the following steps preparation as activeconstituents:
(1) water carries out the heat extraction to mycelium or the sporophore of setting colored Pseudomonas, and this tree bacterium can be Grifola frondosa;
(2) adding alcohol to final volume concentration in the water-soluble extracting liquid of gained is 20-70% (lower concentration interpolation), and described extracting solution is left standstill in 1-25 ℃ in container, and removes and swim in the material on the liquid level or in the liquid or be attached to material on the wall of container; And
(3) adding alcohol to final volume concentration in described extracting solution is 80-90% (high density interpolation), described extracting solution is left standstill in 1-25 ℃, and the precipitation of recovery gained, or after (2) step, described extracting solution is concentrated with the generation precipitation, or be concentrated into described extracting solution dried in common mode.
In the present invention, " Maitake " mushroom (Grifola) can be a Grifola frondosa, white porous tree flower bacterium (Grifola albicans Imaz.), tree flower Pseudomonas umbellate pore furgus (Grifola umbellatus), tree flower Pseudomonas resembles ear orchid etc., and these mushrooms can bright mushroom or the form of dried mushroom use, also can or use its form of powder if necessary with their choppings.
Described heat is extracted in 50-135 ℃ and carried out 15 minutes-3 hours.Be rapid extraction, can carry out this treatment step adding to depress in 100 ℃,, under 2 normal atmosphere, in pressure pan, carry out about 30 minutes to 1 hour or 1 hour for example at about 120 ℃.
Used water is distilled water, purified water, ion exchanged water, tap water or the like.The drying tree flower bacterium of every relatively weight part is adopted the doubly water of (preferred 4-10 doubly) volume of about 4-20.If what adopt is fresh tree bacterium, for the tree bacterium of every weight part, adopt the doubly water of (preferred 2-5 doubly) volume of about 2-10.
In (2) step, the alcohol that joins in the extracting solution can be methyl alcohol, ethanol etc.Adding alcohol to final volume concentration in extracting solution is 20-70%.Can adopt water content is the alcohols of 0-50%.After adding alcohol, in 1-25 ℃ leave standstill 1-20 hour after, just have floating substance on liquid level or in the liquid and occur, perhaps have material to be attached on the wall of container, can be by filtering or these materials being removed with whole pipet, screen cloth etc.
Because with floating substance be attached to material on the wall of container and remove the anti-tumor activity that causes extract and the raising of immune-enhancing activity, this step of removing described material is very important.For this step, must add alcohol to final volume concentration be 20-70%, preferably to final concentration be 30-60%.
Adding alcohol to final volume concentration in (2) solution that obtains of step is 80-99%, preferably to final volume concentration be 80-90% (high density interpolation), make solution at 1-25 ℃ then, preferably leave standstill at 1-5 ℃, to be settled out required material, perhaps, the solution of (2) step gained is concentrated with the generation precipitation under heating, or it is concentrated into dried.
The characteristic of the material of the present invention of gained is as follows:
Outward appearance: brown hygroscopic powder.
Solvability: water-soluble, basic solution and methyl-sulphoxide.
Color reaction: positive in anthrone reaction and ninhydrin reaction.
Aqueous solution characteristic: neutral to slightly acidic.
Molecular weight: about 1000000.
Analysis revealed to gained material of the present invention: its main component is dextran and protein.After the column chromatography purifying, the main component of finding the antitumorigenic substance with immune-enhancing activity of gained of the present invention is dextran/protein complex, wherein dextran and proteinic ratio are mainly 80: 20-99: change between 1, this ratio depends on the quality as the tree bacterium of starting raw material, and the condition of extraction and purifying or the like.
Implement best mode of the present invention (1) extracting method
With 5 liters of distilled water the sporophore of 500 exsiccant Grifola frondosa was extracted 60 minutes down at 120 ℃, adding ethanol to final volume concentration in the 950ml of gained aqueous solution part is 60%.When this solution 4 ℃ leave standstill 12 hours after, on liquid level, in the liquid or on wall of container, have the viscous substance of brownish black to generate.Remove these materials with suction pipe.Add ethanol to final volume concentration at least 80% after, solution is left standstill under 4 ℃ low temperature, obtain the dark brown precipitation of 3g to black.The material of gained is all positive in anthrone reaction and ninhydrin reaction.Behind the column chromatography purifying, find that this material is dextran/protein complex, wherein dextran is 96: 4 with proteinic ratio.
Tsk gel GMPW
XLThe result of the gel filtration chromatography check on the post is to find that its molecular weight is about 1000000.When its dextran partly is hydrolyzed and during with the neutral dextran of high performance liquid chromatography qualitative reaction, has only detected glucose.
Check its protein portion, result to show that this protein is made up of L-glutamic acid, aspartic acid, L-Ala, leucine, Methionin, glycine, Isoleucine, Serine, Xie Ansuan, proline(Pro), Threonine, arginine, phenylalanine, tyrosine, Histidine, tryptophane, methionine(Met), halfcystine etc. with automatic amino acid analyser (only tryptophane efficient liquid phase chromatographic analysis).(2) antitumor test:
Just do not add with the material (hereinafter being referred to as substance A) that obtains in above-mentioned (1) step with in the same mode of step (1) respectively and purely be dissolved in the physiological saline to remove the floating substance on the liquid level or in the liquid or to be attached to the dry substance (hereinafter being referred to as substance B) that the step of the material on the wall of container makes to lower concentration (final volume concentration is 20-70%).To each solution of C3H mouse peritoneal injection of having transplanted the MM-46 cancer 10 times, each dosage is 0.1mg/kg, checks it to the effect that tumor growth suppresses with this, and the result is as shown in table 1.
Table 1
(every group of 15 mouse, ※ t-test: have 5% or lower significant difference).
Measure tumor growth by following formula and suppress (%):
Tumor growth suppresses (%)=[1-(average tumor weight (g) of treatment group/contrast
The average tumor weight (g) of group)] * 100
That group of application of substances A significantly is better than the inhibition effect of application of substances B group to the inhibition effect of tumor growth.
Use after each substances 5 days, gather scavenger cell and killer T cell from the group of control group (only using physiological saline), application of substances A and the group of application of substances B, according to right
3The absorbed dose of H-thymus pyrimidine is surveyed the activity of cellular immunization active cells.The result is as shown in table 2.
Table 2
| Cellular immunization active cells activity ( 3H-thymus pyrimidine specific absorption) | ||
| Scavenger cell | Killer T cell | |
| Control group (using physiological saline) | 100.0 | 100.0 |
| The group of application of substances A | 203.5 | 284.5 |
| The group of application of substances B | 157.2 | 233.7 |
From The above results as can be seen, substance A shows stronger anti-tumor activity and immune-enhancing activity than substance B.
Industrial applicibility
The above results shows, by being that 20-70% produces the material that suspends in the floating and liquid of liquid level or the material on the attached ground chamber wall is removed owing in the hot water water lift liquid of tree flower bacterium, adding alcohol to final volume concentration, can improve immune-enhancing activity and tumor growth and suppress activity.
Therefore, the invention is characterized in, is not to extract simply beta glucan, but effectively prepares the glucan/protein complex with immune-enhancing activity by simple method from limited resource.
The material that makes according to the present invention is hypotoxicity and high security, and can make health food and oral drug, and it is oral with the form of tablet, capsule, liquid, syrup etc. particularly to can be used as anti-tumor agent comprising salmosin.
Claims (5)
1. dextran/protein complex by the following step preparation:
(1) water carries out the heat extraction to mycelium or the sporophore of setting colored Pseudomonas (Grifola), and it is to carry out under 50-135 ℃ 15 minutes-3 hours that described heat is extracted, and this tree bacterium can be Grifola frondosa (Grifola frondosa);
(2) adding alcohol to final volume concentration in the water-soluble extracting liquid of gained is 20-70%, and described extracting solution is left standstill under 1-25 ℃ in container, removes the material that swims on the liquid level or in the liquid or attached to the material on the wall of container; And
(3) adding alcohol to final volume concentration in described extracting solution is 80-99%, and described extracting solution is left standstill at 1-25 ℃, and reclaims the precipitation that produces.
2. dextran/protein complex by the following step preparation:
(1) water carries out the heat extraction to mycelium or the sporophore of setting colored Pseudomonas, and described heat is extracted in carries out 15 minutes-3 hours under 50-135 ℃, and this tree bacterium can be Grifola frondosa;
(2) adding alcohol to final volume concentration in the water-soluble extracting liquid of gained is 20-70%, and described extracting solution is left standstill under 1-25 ℃ in container, removes to swim in the material on the liquid level or in the liquid or be attached to material on the wall of container; And
(3) described extracting solution is concentrated with the generation precipitation, or be concentrated into described extracting solution dried.
3. according to the dextran/protein complex of claim 1 or 2, wherein dextran and proteinic ratio are 80: 20-99: 1.
4. the anti-tumor agent comprising salmosin that has immune-enhancing activity contains the dextran/protein complex as claimed in claim 1 or 2 as activeconstituents.
5. according to the dextran/protein complex of claim 1 or 2, join wherein that water carries out to the mycelium of setting colored Pseudomonas or sporophore that heat is extracted and water-soluble extracting liquid in alcohol have the final volume concentration of 30-60%.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8051880A JP2859843B2 (en) | 1996-03-08 | 1996-03-08 | Antitumor substance extracted from Maitake |
| JP51880/1996 | 1996-03-08 | ||
| JP51880/96 | 1996-03-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1213378A CN1213378A (en) | 1999-04-07 |
| CN1120173C true CN1120173C (en) | 2003-09-03 |
Family
ID=12899202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97192894A Expired - Lifetime CN1120173C (en) | 1996-03-08 | 1997-03-07 | Antitumor substance extracted from Grifola |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5854404A (en) |
| EP (1) | EP0893449B1 (en) |
| JP (1) | JP2859843B2 (en) |
| CN (1) | CN1120173C (en) |
| AU (1) | AU2232997A (en) |
| DE (1) | DE69730420T2 (en) |
| WO (1) | WO1997032896A1 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2859843B2 (en) * | 1996-03-08 | 1999-02-24 | 株式会社雪国まいたけ | Antitumor substance extracted from Maitake |
| US6616928B1 (en) * | 1998-10-20 | 2003-09-09 | Yukiguni Maitake Co., Ltd. | Active oxygen scavenger and cancer chemopreventer from Grifola |
| JP2001097881A (en) * | 1999-09-28 | 2001-04-10 | Yukiguni Maitake Co Ltd | Cancer prophylaxis agent, and cancer prophylaxis food or feed all derived from grifola frondosa |
| JP2001172194A (en) * | 1999-12-17 | 2001-06-26 | Yukiguni Maitake Co Ltd | Nitrogen monoxide (no)-production inducer originating from grifola frondosa (a kind of mushroom) |
| CA2425954A1 (en) * | 2000-04-29 | 2002-11-08 | Eric A. Scheinbart | Compositions and methods for treatment of multiple myeloma |
| KR100501039B1 (en) * | 2000-08-23 | 2005-07-18 | 한국 한의학 연구원 | Grifola frondosa extracts for controling side effect of cisplatin |
| US7507724B2 (en) * | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| KR100740893B1 (en) * | 2001-04-19 | 2007-07-19 | 충남대학교산학협력단 | Anti-Cancer Compositions Containing Glycoprotein KGF-1 |
| AU2002322702A1 (en) * | 2001-07-27 | 2003-02-17 | Tanical Therapeutics, Inc. | Grifola extracts and methods of use thereof |
| WO2004092334A2 (en) * | 2003-04-09 | 2004-10-28 | Jarrow Formulas, Inc. | Methods of producing edible fungi containing activated folates and nutritional supplements containing activated folates |
| JP4686116B2 (en) * | 2003-05-01 | 2011-05-18 | 株式会社雪国まいたけ | Neurotrophic factor-like agent |
| CA2455655C (en) * | 2003-07-18 | 2011-11-08 | Shirota, Masaki | A glycoprotein with antidiabetic, antihypertensive, antiobesity and antihyperlipidemic effects from grifola frondosa, and a method for preparing same |
| JP4842507B2 (en) * | 2003-11-19 | 2011-12-21 | 株式会社雪国まいたけ | Anti-influenza virus activator |
| CN1322141C (en) * | 2004-09-22 | 2007-06-20 | 中国食品发酵工业研究院 | Method of preparing huishuhua (grey tree flower) polysaccharide by enzymolysis |
| JP2006273835A (en) * | 2005-03-04 | 2006-10-12 | Michishi Tani | Therapeutic agent for malignant tumor and food or beverage containing the same |
| JP2007031665A (en) * | 2005-07-29 | 2007-02-08 | Yukiguni Maitake Co Ltd | Glycoprotein extracted from grifola frondosa |
| KR100729213B1 (en) * | 2005-07-29 | 2007-06-19 | 주식회사 라이벌코리아 | Exo-biopolymer isolated from submerged mycelial culture of Grifola frondosa increasing immune activity |
| US7597910B2 (en) * | 2005-08-20 | 2009-10-06 | Slgm Medical Research Institute | Compositions and methods for treating prostate disorders |
| JP2008106018A (en) | 2006-10-27 | 2008-05-08 | Yukiguni Maitake Co Ltd | Substance having anti-influenza virus activity derived from grifola frondosa and its manufacturing method |
| JP2008161109A (en) | 2006-12-28 | 2008-07-17 | Yukiguni Maitake Co Ltd | Method for preventing disease of baby pig in weaning period |
| JP2008161120A (en) | 2006-12-28 | 2008-07-17 | Yukiguni Maitake Co Ltd | Mother pig rearing method |
| JP5153188B2 (en) * | 2007-03-30 | 2013-02-27 | 小林製薬株式会社 | Th1 / Th2 balance improver |
| JP2009191009A (en) | 2008-02-14 | 2009-08-27 | Yukiguni Maitake Co Ltd | Low molecular substance derived from grifola frondosa having immunostimulatory activity and antitumor activity |
| US20100178279A1 (en) * | 2009-01-15 | 2010-07-15 | Cornell University | Beta-Glucan Enhances Hematopoietic Progenitor Cells Engraftment and Promotes Recovery from Chemotoxicity |
| JP2011184306A (en) * | 2010-03-04 | 2011-09-22 | Yukiguni Maitake Co Ltd | Substance derived from grifola spp. mushroom suppressing elevation of postprandial hyperglycemia |
| US8597697B2 (en) | 2011-06-24 | 2013-12-03 | Nutragenesis, Llc | Composition of beta-glucan and ashwagandha |
| CN103059160B (en) * | 2011-10-20 | 2015-12-02 | 中国科学院上海药物研究所 | Beta-glucan GFPBW1 and its production and use |
| CN103304680B (en) * | 2012-03-09 | 2017-02-08 | 中国科学院上海药物研究所 | Beta-glucan, and extraction method and application thereof |
| US10688158B2 (en) | 2012-07-05 | 2020-06-23 | Nutramax Laboratories, Inc. | Compositions comprising sulforaphane or a sulforaphane precursor and a milk thistle extract or powder |
| CN104906150A (en) * | 2015-06-10 | 2015-09-16 | 云南大学 | Application of grifola frondosa in preparation of anti-depression products |
| CN104825499B (en) * | 2014-10-28 | 2020-04-03 | 云南大学 | Application of maitake mushroom extract in preparation of anti-depression drug |
| WO2016066102A1 (en) * | 2014-10-28 | 2016-05-06 | 云南大学 | Use of maitake and maitake grifolan d component in preparation of antidepressant drug |
| CN107541533B (en) * | 2017-06-13 | 2021-03-19 | 湖南民康生物技术研究所 | Preparation method of medicinal and edible fungi hypha polysaccharide polypeptide immunopotentiator |
| CN108586590B (en) * | 2018-04-26 | 2020-11-10 | 中国医学科学院药用植物研究所 | Application of grifola frondosa and grifola frondosa polysaccharide peptide in promoting in vivo mercury discharge |
| US20220387535A1 (en) | 2021-05-26 | 2022-12-08 | Nutramax Laboratories, Inc. | Compositions comprising sulforaphane or a sulforaphane precursor and moringa plant components |
| CN114230646B (en) * | 2021-12-07 | 2023-07-04 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | Antitumor grifola frondosa glycoprotein and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06312934A (en) * | 1993-04-30 | 1994-11-08 | Yukiguni Maitake:Kk | Production of substance having immunosuppressive effect |
| JPH0769913A (en) * | 1993-09-02 | 1995-03-14 | Yukiguni Maitake:Kk | Production of substance having aids-curing effect |
| JPH09238697A (en) * | 1996-03-08 | 1997-09-16 | Yukiguni Maitake:Kk | Antitumor substance extracted from grifola frondosa |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59210901A (en) * | 1983-05-17 | 1984-11-29 | Nippon Kinoko Kenkyusho | Glucan having beta-1,6 bond-containing main chain, obtained from maitake and antineoplastic agent comprising same |
| JPS60255733A (en) * | 1984-05-30 | 1985-12-17 | Nippon Beet Sugar Mfg Co Ltd | Beta-d-glucan |
| JPS62209091A (en) * | 1986-03-08 | 1987-09-14 | Nippon Beet Sugar Mfg Co Ltd | Antitumor active polysaccharide |
| JPH08119874A (en) * | 1994-10-24 | 1996-05-14 | Takumi Sogabe | Production of suppressor of aids virus and cancer cell |
| JPH08131133A (en) * | 1994-11-09 | 1996-05-28 | Nippon Chrome Kogyo Kk | Production of health drink containing 'maitake' extract |
| JPH08291078A (en) * | 1995-04-21 | 1996-11-05 | M I O:Kk | Mushroom protein for food and beverage effective in preventing and treating hypertension and hyperlipemia and having antitumor action, mushroom protein for food and beverage effective in preventing and treating obesity and having antitumor action and method for extracting these proteins |
-
1996
- 1996-03-08 JP JP8051880A patent/JP2859843B2/en not_active Expired - Lifetime
-
1997
- 1997-03-06 US US08/812,795 patent/US5854404A/en not_active Expired - Lifetime
- 1997-03-07 DE DE69730420T patent/DE69730420T2/en not_active Expired - Lifetime
- 1997-03-07 CN CN97192894A patent/CN1120173C/en not_active Expired - Lifetime
- 1997-03-07 WO PCT/JP1997/000728 patent/WO1997032896A1/en active IP Right Grant
- 1997-03-07 EP EP97905467A patent/EP0893449B1/en not_active Expired - Lifetime
- 1997-03-07 AU AU22329/97A patent/AU2232997A/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06312934A (en) * | 1993-04-30 | 1994-11-08 | Yukiguni Maitake:Kk | Production of substance having immunosuppressive effect |
| JPH0769913A (en) * | 1993-09-02 | 1995-03-14 | Yukiguni Maitake:Kk | Production of substance having aids-curing effect |
| JPH09238697A (en) * | 1996-03-08 | 1997-09-16 | Yukiguni Maitake:Kk | Antitumor substance extracted from grifola frondosa |
Also Published As
| Publication number | Publication date |
|---|---|
| US5854404A (en) | 1998-12-29 |
| EP0893449A1 (en) | 1999-01-27 |
| EP0893449A4 (en) | 1999-04-07 |
| AU2232997A (en) | 1997-09-22 |
| CN1213378A (en) | 1999-04-07 |
| JP2859843B2 (en) | 1999-02-24 |
| DE69730420D1 (en) | 2004-09-30 |
| WO1997032896A1 (en) | 1997-09-12 |
| DE69730420T2 (en) | 2005-09-08 |
| JPH09238697A (en) | 1997-09-16 |
| EP0893449B1 (en) | 2004-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1120173C (en) | Antitumor substance extracted from Grifola | |
| US6783771B2 (en) | Physiologically active substance EEM-S originating in mushrooms, process for producing the same and drugs | |
| CN105524967B (en) | A kind of combined preparation process of sea cucumber polysaccharide and holothurian collagen polypeptide | |
| CN1507772A (en) | Method for preparing hickory chick by liquid deep fermentation and product thereof | |
| US20180193373A1 (en) | Method for Preparing Linseed Polysaccharide Having Antiviral Activity and Immunological Activity, and Use of the Linseed Polysaccharide | |
| CN1803836A (en) | Jellyfish collagen and method for preparing the same | |
| CN1290867C (en) | Polysaccharide of echinacea angustifolia | |
| CN104774255B (en) | The biologically active peptide in jellyfish source and preparation method thereof | |
| CN101029087A (en) | Method for separating polysaccharide against growth of cancer cells from dictyophord | |
| Zhuang et al. | Chemical modification and antitumor activity of polysaccharides from the mycelium of liquid-cultured Grifola frondosa | |
| JP2000159808A (en) | Method for separating and purifying basidiomycota hypha extract | |
| EP2087899B1 (en) | Grifola frondosa-derived substance having anti-influenza virus activity and method for producing the same | |
| US6093694A (en) | Antitumor active substances | |
| JP2005068112A (en) | Extract from grifola frondosa (a kind of mushroom) and glycoprotein and method for producing the same | |
| JPH05117303A (en) | Water-soluble polysaccharide originating from yamabushitake (fungus) and antitumor agent mainly containing the same | |
| CN1482144A (en) | Method for preparing galactomannanpeptide and product | |
| KR20220076576A (en) | Method for separating water-soluble extract and fat-soluble extract containing betaglucan from mushroom | |
| CN1205230C (en) | Water soluble heteropolysaccharide and its preparing method and use | |
| CN105200104A (en) | Method for preparing antioxidative peptide chain by utilizing crab shell offal | |
| CN106916206A (en) | Hard clam polypeptide and preparation method and application | |
| CN105198962A (en) | Defatted crab shell antioxidative polypeptide | |
| CN117143949B (en) | Euphausia superba source high F value oligopeptide and application thereof in liver protection | |
| CN110699410A (en) | Preparation method of euphausia superba small-molecule peptide | |
| AU2021104232A4 (en) | Application of sanghuangporus sanghuang fermentation broth polysaccharides in medicaments of anti-avian influenza virus | |
| CN108586590B (en) | Application of grifola frondosa and grifola frondosa polysaccharide peptide in promoting in vivo mercury discharge |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20030903 |
|
| CX01 | Expiry of patent term |